Case-Based Discussion of Thyroid Cancer Therapy
|
|
- Reynard Holmes
- 5 years ago
- Views:
Transcription
1 Case-Based Discussion of Thyroid Cancer Therapy Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology The Ohio State University Co-Leader, Molecular Biology and Cancer Genetics Program Arthur G. James Comprehensive Cancer Center The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2 Disclosures Funding from NIH Member NCCN Thyroid Cancer Guidelines Panel Not member of ATA Guidelines Panel 2
3 Clinical Case: Primary Evaluation 23 year old woman who noted a lump in the neck in 5/2015. She saw her physician who thought it was likely a node. She had no other symptoms. TSH was normal in 1/2015 at an annual physical. It did not resolve and in 9/2015 she had a neck CT with contrast. CT with right lobe nodules and nodes in the neck felt to be normal size but perhaps more on right than left. Ultrasound revealed two right lobe nodules; 2.4x2.5x2.1 cm, palpable, spongiform 1.4x1.8x0.7 cm with calcifications, irregular border, posterior invasion, hypervascularity Nodes not reported or visualized Referred for Evaluation 3
4 2016 ATA Guidelines approach to this patient Laboratory Evaluation? TSH is recommended. Calcitonin can be considered. Adequate Ultrasound? Guidelines recommend lymph node evaluation as part of a thyroid ultrasound Fine Needle Aspiration? Yes. Based on report, choice of nodule based on pattern recognition. Haugen, et al Thyroid
5 2016 Guidelines Nodule FNA Selection Table 8: Ultrasound features of lymph nodes predictive of malignant involvement. (adapted with permission from the European Thyroid Association guidelines for cervical ultrasound Sign Reported sensitivity % Reported specificity % Microcalcifications Cystic aspect Peripheral vascularity Hyperechogenicity Round shape Haugen, et al Thyroid 2016
6 Case: Neck Ultrasound Confirms the presence of the two nodules but also Neck Nodes Right jugular nodes; level 3 and 2A with malignant characteristics; largest is posterior to the jugular vein measuring 0.8x0.9x1.5 cm Right posterior triangle node that is solid with hypervascularity measuring 2.3x2.1x2.2 cm. Left Lobe normal No concerning nodes in the left central or lateral neck TSH is 0.68 mu/l Review of CT images also demonstrated concerning nodes in the right lateral neck; none in mediastinum; no clear tracheal invasion
7 Case: Ultrasound-guided FNA of the right posterior node Three Passes: Smears from all three; hub washout from two passes for Tg measurement; one hub washout for liquid preparation FNA Tg: 11,740 ng/ml; serum Tg is 75 ng/ml Cytology: Consistent with Papillary Thyroid Cancer The Nodule was not aspirated in this circumstance
8 Next Steps per the ATA 2016 Guidelines Surgery Recommendation: For intrathyroidal nodules without nodes hemithyroidectomy or total thyroidectomy are acceptable options. For more extensive disease, total thyroidectomy and compartmental node dissection in selected cases with involved nodes is recommended. Surgery Performed: Total thyroidectomy, central neck dissection, lateral neck dissection to include the involved compartments of the neck Haugen, et al Thyroid 2016
9 Surgical Pathology 2.1x.1.7 PTC with local invasion into muscle and 5 sites of vascular invasion 3/14 nodes positive in the central neck, all < 5 mm 4/14 nodes in the jugular chain positive: largest 1.2 cm with extranodal invasion 2/46 nodes in the lateral neck; the largest is 2.4 cm with no local invasion Radiology: CT of the chest without contrast with no evidence of lung metastases
10 AJCC 8 th Edition/ TNM System Identify High-Risk Patients in whom mortality may be increased Allow Accurate Communication Maintain Common Cancer Registries Does not Predict Residual/Recurrent Disease Firm Age Cut-off that may not match clinical severity of disease Does not account well for extent of surgery AJCC Cancer Staging Manual, 8 th Edition (2016), Springer Publishing
11 Revised ATA Initial Risk Stratification Low Risk for Recurrence Intrathyroidal differentiated 1-4 cm No Local or Vascular Invasion 5 LN micromets ( 2mm) Minimally Invasive FTC (Capsular Invasion or minor Vascular Invasion) Intermediate Risk for Recurrence Everything not in Low or High Risk ~40% High Risk Variants of DTC Intrathyroidal 1-4 cm or multifocal micro PTC with local invasion if BRAF V600E ; Nodes 2 mm up to 3 cm High Risk for Recurrence Gross Extrathyroidal Extension Incomplete Resection; Large Nodes (>3 cm) Distant Metastases; Extensive Vascular Inv. FTC Modified from Erik Alexander ~15% ~80%
12 What is the Staging and Risk Category for This Patient? TNM: Stage 1 or Stage 2 T4a N1b Mx (M0 based on the CT scan) Excellent Anticipated Long Term Survival ATA Risk Category High Risk for Residual disease or Recurrence Molecular Testing of Tumor Not Performed, No Impact on Therapeutic Decisions at This Time
13 Should I-131 be Administered? Recommendations Based on Risk Stratification of High Risk: YES Preparation and Dosing RhTSH vs Thyroxine Withdrawal Pt and Physician Preference Dosing based on goals of therapy Adjuvant Therapy for Probably Residual Disease 13
14 Continued Postoperative Restaging Pt on L-T4. TSH 0.35; Tg 3.2 six weeks after surgery TSH: 0.12; Tg: 0.4 three months after surgery Neck Ultrasound with postoperative change and no identifiable residual thyroid cancer. Should I-131 be administered? If so, what preparation and dose?
15 Guidelines 2016 Recommendation Recommendation 56: When RAI is intended for initial adjuvant therapy to treat suspected microscopic residual disease, administered activities above those used for remnant ablation up to 150 mci are generally recommended (in absence of known distant metastases). Weak recommendation, Low-quality evidence Haugen, et al Thyroid 2016
16 Treatment Decision Based on pathology and clinical features, I-131 was recommended Dose was determined based on: Post-operative Staging Pre-therapy scan Patient wishes Pre therapy scan: Thyroid bed uptake only Dosed with 100 mci I-131 Stimulated Tg: 28 ng/ml Post-therapy scan with thyroid bed and lung metastases 16
17 Post-treatment Course 6 months later: Tg <0.1 ng/ml with TSH 0.06 mu/l and normal Free T4 Two episodes of significant sialoadenitis Otherwise doing well 17
18 RESPONSE TO THERAPY STAGING Response to Therapy Excellent Response: Suppressed Tg <0.2 or Stim Tg <1.0 Negative Ultrasound Incomplete Biochemical Response Suppressed Tg >1.0 or Stim Tg <10 Negative Ultrasound Incomplete Structural Response Structural Evidence of Disease Indeterminate Response TgAb+ Stable or declining Suppressed Tg or Stim Tg Indeterminate Imaging Recommendations: Decrease Intensity and Frequency of Follow-up and TSH Suppression Stable/Lower Tg - Observe Rising Tg Additional Investigations Consider Additional Investigations & Therapies Continued Observation and Testing
19 Response Status of the Patient Excellent Response Based on Tg With Distant Mets Plan for the following TSH-stimulated Tg Chest CT without Contrast Neck Ultrasound Once completed will have a more complete assessment of response to therapy. 19
20 Persistent/Recurrent Local Thyroid Cancer: Case 2
21 Case 2 43 year old white woman diagnosed with a 2.0 cm leftsided intrathyroidal papillary thyroid cancer with 0/1 nodes with evidence of nodal spread at age 27 in Stage 1 T2N0Mx PTC She was treated with 100 mci of I-131 for remnant ablation following thyroxine withdrawal. She had uptake in the thyroid bed on pre and posttherapy scans.
22 Case : She had a negative 5 mci I-131 whole body scan following thyroxine withdrawal Serum Tg was 3.5 ng/ml with negative anti-tg antibodies and she was treated with 150 mci I-131. Post-therapy scan had minimal uptake in the thyroid bed. She had negative diagnostic I-131 scans in 1994 and also was after rhtsh and her Tg level stimulated to 5.5 ng/ml She had a negative CT of the neck with contrast and a negative thyroid ultrasound in Basal Tg levels are between 0.6 and 1.2 ng/ml with TSH levels between 0.02 and 0.4 mu/l.
23 Case 2 After delivery of a healthy child she is referred for evaluation of thyroglobulin positive, scan negative persistent papillary thyroid cancer.
24 Case 2 She has no personal history of radiation exposure She denies hoarse voice or dysphagia. The remainder of her medical history and her physical examination are unremarkable. She has no palpable neck adenopathy or tissue in the thyroid bed.
25 Case 2 Laboratories:TSH: 0.05 mu/l; Tg: 0.5 ng/ml; anti-tg antibodies are negative. What would you recommend at this point? A. PET/CT B. Neck Ultrasound C. Chest CT without IV contrast D. No additional imaging E. B and C
26 PET/CT in Tg positive, Scan Negative Thyroid Cancer Shammas, et al. retrospectively reported PET/CT data on 61 patients with suspected recurrent thyroid cancer 51 with Tg positive, I-131 scan negative disease True Positive results were noted in 26/61 23 patients had resectable tumor recurrence mostly in the neck and/or mediastinum. Neck ultrasound was not routinely performed New distant metastases were identified in the lungs (n=5) and bones (n=3). Shammas, et al J Nucl Med 2007:48;
27 PET/CT Tg positive, Scan Negative Thyroid Cancer: Tg level correlation True positive PET/CT based on Tg levels: Stimulated Tg: <5 ng/ml: 22% 5-10 ng/ml: 28.5% >10 ng/ml: 60.8% Basal Tg: <5 ng/ml: 8.3% 5-10 ng/ml: 75% >10 ng/ml: 66.7% No obvious difference when performed with a suppressed or elevated TSH level in this study. Shammas, et al J Nucl Med 2007:48;
28 Does rhtsh stimulation improve FDG PET accuracy? Leboullex, et al. (J Clin Endocrinol Metab. 2009: 94: ) PET/CT performed before and hours after rhtsh in 63 patients with DTC rhtsh enhanced the number of lesions detected overall rhtsh PET/CT did not increase the number of patients with any detected lesions. 8 lesions were found only by rhtsh PET/CT 4 of these 8 were thyroid cancer on pathology and 4 were not. rhtsh administration led to treatment changes for proven thyroid cancer in 6% of cases, this was not statistically significant.
29 Neck Ultrasound to Detect Residual/Recurrent Thyroid Cancer Castagna, et al reported on a cohort of patients with undetectable stimulated Tg one year after I-131 therapy (n=68) 67 patients underwent neck ultrasound 2.5 yrs later 1 patient (1.5%) developed a recurrence at follow up detected by neck ultrasound, but not basal Tg. Authors Conclusion: Neck Ultrasound is the most sensitive method for detecting recurrent PTC in lowrisk patients. Castagna MG. J Clin Endocrinol Metab 2008: 93;
30 Case 2 Neck ultrasound was performed.
31 ATA Guidelines on Node Evaluation Recommendation 65: If a positive result would change management, ultrasonographically suspicious lymph nodes greater than 8-10 mm in the smallest diameter should be biopsied for cytology and thyroglobulin measurement in the needle washout fluid. Weak rec, low quality of evidence Suspicious lymph nodes less than 8-10 mm in largest diameter may be followed without biopsy with consideration for intervention if there is growth or in the node threatens vital structures. Weak rec, low quality of evidence Haugen, et al. Thyroid 2016
32 Tg on FNA of Nodes: Clinical Practice Points Wash out hub in total 1.0 ml volume of saline Typically perform 3 passes in a node. All have smears for cytology; for 2 passes the hub is washed in the 1 cc of saline and for the third pass, the hub wash is put into liquid medium for pathology. Tg sample is put on ice. Positive result if Tg>10 ng/ml in the node and > circulating level. Often times in the thousands. True positive value uncertain as is the role of different sample dilutions between studies but has varied between 1 and 10. Not affected by circulating anti-tg antibodies (Snozek et al J Clin Endocrinol Metab 2007; 92: )
33 Efficacy of Reoperation: OSU Experience 107 surgeries were undertaken in 70 patients. Biochemical CR (Stim Tg< 0.2) was initially achieved in 12 (17%) patients. 28 of 58 people with detectable postoperative Tg went on to re-exploration with biochemical CR in 5 (18%). 2 other patients had a delayed CR after one reoperation In total, CR was achieved in 19 patients (27%) with 60 months follow-up (range 4-116). 46% achieved a stimulated Tg < 2.0 ng/ml. 3% new hypoparathyroidism; no new RLN damage Al-Saif O, Farrar WM, Bloomston M, Porter K, Ringel MD, Kloos RT J Clin Endocrinol. Metab. 2010; 95(5):
34 ATA Guidelines Management of Residual/Recurrent Thyroid Cancer in the Neck Rec 71: Therapeutic comprehensive compartmental lateral and/or central neck dissection, sparing uninvolved vital structures, should be performed for patients with biopsyproven perisistent or recurrent disease for central neck nodes >8 mm and lateral neck nodes >10 mm in smallest dimension that can be localized on anatomic imaging. Recommendation: Strong; Evidence: Moderate Rec 73 (C24): For regional nodal metastases discovered on Dx WBS, RAI may be employed in patients with lowvolume disease or in combination with surgery, although surgery is typically used in the presence of bulky disease or disease amenable to surgery. Haugen, et al Thyroid 2016
35 Case 2 FNA of the node was consistent with papillary thyroid cancer on cytology; Tg level in the node was 1830 ng/ml. Chest CT had no evidence of distant metastases What would you recommend now? A. Surgery B. I-131 Therapy C. Monitor with no surgery
36 Case 2 The neck was marked at the site of the nodes and a limited right lateral neck dissection was performed. 1 of 4 nodes removed had PTC The malignant node measured 1.7x cm What would you do next?
37 Case 2 3 months after surgery: TSH with a Tg 0.3 ng/ml with negative antibodies 6 months after surgery: TSH: <0.04 with Tg <0.2 with negative antibodies 8 months after surgery: rhtsh Tg is 0.4 ng/ml 12 months after surgery: TSH 0.13 mu/l; Tg <0.2 ng/ml with negative anti-tg antibodies. 24 months after surgery: rhtsh Tg is <0.2 ng/ml and neck US is negative
38 38 Metastatic Thyroid Cancer: Case 3
39 Case 3 51 year old gentleman with right-sided thyroid nodule diagnosed in 2003 Right hemithyroidectomy was performed Pathology read as a 2.5 cm encapsulated non-invasive follicular carcinoma without evidence of either capsular or lymphovascular invasion. Reviewed by two pathologists at that time. Subsequent pathology review: Well-differentiated tumor of undetermined malignant potential. What would you recommend?
40 Case 3 Options for this patient Completion thyroidectomy Monitor by Tg and ultrasound Remnant lobe ablation
41 Case 3 After discussion with the patient he was monitored without a second surgery. Thyroid Ultrasound with residual tissue in the right lobe and a normal size left lobe with no nodules. From Tg levels between 7 and 13 ng/ml with positive anti-tg antibodies at 28 mu/l and TSH levels in the mu/l range.
42 Case 3 After discussion with the patient he was monitored without a second surgery. Thyroid Ultrasound with residual tissue in the right lobe and a normal size left lobe with no nodules. From Tg levels between 7 and 13 ng/ml with positive anti-tg antibodies at 28 mu/l and TSH levels in the mu/l range.
43 Case : Tg levels increase to the ng/ml with the same degree of TSH suppression with continued anti-tg antibodies at 56 mu/l. PET/CT imaging was performed and was negative for FDG-avid lesions. Neck ultrasound is unchanged He is referred to OSU for evaluation.
44 Case 3 The patient is managed on 137 mcg of L-thyroxine daily and metoprolol for heart palpitations. Exam is unremarkable TSH: 1.57 mu/l; Tg 34.2 ng/ml with positive anti- Tg antibodies at 72 mu/l. What diagnostic tests would you perform? Are the Tg or anti-tg antibodies reliable markers?
45 Effects of Anti-Tg antibodies on Tg Immunometric Assays Tg antibodies generally reduce measured Tg levels in the immunometric assays used by most laboratories. Measurable Tg levels in the setting of positive antibodies might reflect a non-interfering antibody, or an underestimate of the actual Tg levels Ringel MD and Nabhan F. J Clin Endocrinol Metab. 2014
46 Effects of Anti-Tg antibodies on Tg Immunometric Assays Tg antibodies generally reduce measured Tg levels in the immunometric assays used by most laboratories. Measurable Tg levels in the setting of positive antibodies might reflect a non-interfering antibody, or an underestimate of the actual Tg levels Ringel MD and Nabhan F. J Clin Endocrinol Metab. 2014
47 Case 3 Neck ultrasound confirmed residual tissue in the thyroid bed, a normal left lobe and no concerning neck nodes. CT of the chest without contrast revealed multiple pulmonary nodules in a lower lobe distribution bilaterally.
48 Case 3 Neck ultrasound confirmed residual tissue in the thyroid bed, a normal left lobe and no concerning neck nodes. CT of the chest without contrast revealed multiple pulmonary nodules in a lower lobe distribution bilaterally.
49 Case 3 What would you do now? Completion Thyroidectomy I-131 therapy Neither Both
50 Case 3 The patient was referred for a completion thyroidectomy. The residual tissue in the right bed and a left lobectomy were performed Normal thyroid tissue was removed. Post-op labs: TSH: 2.18 mu/l; Tg: 34.8 ng/ml with Tg Antibody level of 30 mu/l
51 Case 3 The patient was withdrawn from L-thyroxine. TSH: 35.5 mu/l; Tg 160 ng/ml; anti-tg antibodies <20 mu/l Pre-therapy scan with minimal uptake in the thyroid bed. 217 mci of I-131 administered Post-therapy scan with uptake in the thyroid bed and faint uptake in the lower lung fields consistent with pulmonary metastases
52 Case 3: Questions to Consider Why was the PET/CT negative? Lack of avidity Small size of nodules What is the patient s prognosis with small PET negative pulmonary metastases?
53 Kaplan-Meier survival plots of thyroid cancer patients based on the location of metastases Robbins, R. J. et al. J Clin Endocrinol Metab 2006;91: Copyright 2006 The Endocrine Society
54 Kaplan-Meier survival plots of thyroid cancer patients based on PET scan SUVmax Copyright 2006 The Endocrine Society Robbins, R. J. et al. J Clin Endocrinol Metab 2006;91:
55 Case 3 4 months after I-131 therapy: TSH: 0.24 mu/l; Tg: 17.7 ng/ml with anti-tg antibodies <20 mu/l. ~12 months after therapy; Tg 44 ng/ml with negative anti-tg antibodies. Chest CT with mild progression, largest lesion 0.9x1.0 cm. Most recent labs: TSH: 0.036; Tg: 84 ng/ml (- antibodies) CT scan: Slow progression with the largest nodule 13x10 mm. Neck ultrasound was negative. Lung lesions not FDG Avid on Repeat PET/CT. No other mets noted What are the options now?
56 Case 3 Options for consideration Repeat I-131 Therapy Treatment off label with a FDA-approved kinase inhibitor previously studied in differentiated thryoid cancer Sorafenib, Sunitinib, Pazopanib Clinical Trial but rate of progression is currently too slow to qualify (good news!!) Continue to Monitor with no therapy
57 Case 3 Issues to Consider Prognosis based on Imaging and Tg Levels Likelihood of Remission or Stabilization with Treatment Side effects of treatment vs current quality of life (which is excellent) Now has developed T11 bone met requiring surgery and stereotactic radiotherapy Toxicities and Quality of Life Expected Response
58 Tg Doubling Time Predicts Outcome Tg Doubling Time (DT): Miyauchi A, et al Thyroid patients with at least 4 serial Tg levels with TSH <0.1 and no anti-tg antibodies for calculation of doubling time. 137 had detectable Tg levels DT<1 Yr: 87.5% 5 yr survival; 50% 10 Yr survival DT 1-3 Yrs: 95% 5Yr survival; 95% 10 Yr survival DT >3 Yrs: 100% 5 Yr survival; 100% 10 Yr survival
59 Thyroid Cancer Kinase Inhibitors: Primary Active Targets Drug VEGFR2/3 RET BRAFV600E BRAF WT MEK 1/2 cmet PDGF Axitinib X Cabozantinib X X X Dabrafenib X Lenvatinib X X X, FGFR1 Motesanib X X X Pazopanib X X X, C-KIT Selumetinib X Sorafenib X X X Sunitinib X X Vandetinib X X EGFR Vemurafanib X
60 Tyrosine Kinase Inhibitors in Differentiated Thyroid Cancer: Clinical Trials Efficacy Pennell NA, et al Thyroid, 2008: 18:317-23; 2 Sherman SI, et al. N Engl J Med. 2008:359: Cohen EE, et al J Clin Oncol 2008: 26: Gupta-Abramson V, et al.j Clin Oncol. 2008: 26: Kloos RT and Ringel MD, et al J Clin Oncol. 2009: 27: Bible, et al Lancet Oncol. 2010:11: Schlumberger, et al N Engl J Med. 2015
61 Tyrosine Kinase Inibitors: Caveats Side Effects Fatigue, Rash, and others GI: including fistulae and perforations including some fatalities Hypertension and Cardiac Side Effects Most studies show best response. Duration can be variable and side effects may worsen over time Limit use to patients with high expected mortality from thyroid cancer
62 Sorafenib Improves Progression Free Survival in Patients with Progressive DTC Progression-Free Survival Best Tumor Response Brose, et al. Lancet 4/2014 epub 62
63 Lenvatinib Phase III Study: of Progression-free Survival in the Intention-to-Treat Population. Schlumberger M et al. N Engl J Med 2015;372:
64 Kinase Inhibitors Thyroid Cancer: Patient Selection for Treatment Patients that are appropriate for kinase inhibitor therapies for thyroid cancer have surgical and iodine non-responsive, typically life-threatening, and radiographic progressive or anaplastic thyroid cancer Lenvatinib is often the first line Side Effects May Determine Choice of Drug 1-2 % Drug Related death rate in all studies Ongoing studies to start low and increase
65 Summary Individualize Thyroid Cancer Treatment Initial Therapy with I-131 and Degree of TSH suppression Local Residual/Recurrent Disease Distant Metastases
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More informationStrategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer
Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer A rational approach to longterm follow-up based on dynamic risk assessment. World Congress on Thyroid
More informationRisk Adapted Follow-Up
Risk Adapted Follow-Up Individualizing Follow- Up Strategies R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Medical College
More informationGerard M. Doherty, MD
Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston
More informationWTC 2013 Panel Discussion: Minimal disease
WTC 2013 Panel Discussion: Minimal disease Susan J. Mandel MD MPH Panelists Ken Ain Yasuhiro Ito Stephanie Lee Erich Sturgis Mark Urken Faculty/Presenter Disclosure Relationships with commercial interests
More informationDynamic Risk Stratification:
Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine
More informationHow good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status
New Perspectives in Thyroid Cancer Jennifer Sipos, MD Assistant Professor of Medicine Division of Endocrinology The Ohio State University Outline Thyroid Nodules Thyroid Cancer Epidemiology Initial management
More informationPreoperative Evaluation
Preoperative Evaluation Lateral compartment lymph nodes are easier to detect and are amenable to FNA Central compartment lymph nodes are much more difficult to detect and FNA (Tg washout testing is compromised)
More informationHow Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017
How Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017 Bryan R. Haugen, MD University of Colorado, School of Medicine Outline Some statistics New guidelines
More informationDifferentiated Thyroid Cancer: Initial Management
Page 1 ATA HOME GIVE ONLINE ABOUT THE ATA JOIN THE ATA MEMBER SIGN-IN INFORMATION FOR PATIENTS FIND A THYROID SPECIALIST Home Management Guidelines for Patients with Thyroid Nodules and Differentiated
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationA Review of Differentiated Thyroid Cancer
A Review of Differentiated Thyroid Cancer April 21 st, 2016 FPON Webcast Jonn Wu BMSc MD FRCPC Radiation Oncologist, Vancouver Centre Chair, Provincial H&N Tumour Group, BCCA Clinical Associate Professor,
More informationI-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Advances in Medical and Surgical Management of Thyroid Cancer January 23-24, 2015 I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER 2015 Leonard Wartofsky,
More informationApproach to Thyroid Nodules
Approach to Thyroid Nodules Alice Y.Y. Cheng, MD, FRCPC Twitter: @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationManagement of Recurrent Thyroid Cancer
Management of Recurrent Thyroid Cancer Eric Genden, MD, MHA Isidore Professor and Chairman Department of Otolaryngology- Head and Neck Surgery Senior Associate Dean for Clinical Affairs The Icahn School
More informationMedullary Thyroid Carcinoma: New Therapies and Trials
Medullary Thyroid Carcinoma: New Therapies and Trials Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology, Diabetes, and Metabolism The Ohio State University
More informationAnca M. Avram, M.D. Professor of Radiology
Thyroid Cancer Theranostics: the case for pre-treatment diagnostic staging 131-I scans for 131-I therapy planning Anca M. Avram, M.D. Professor of Radiology Department of Nuclear Medicine University of
More informationPEDIATRIC Ariel Katz MD
PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationPediatric Thyroid Cancer Lung Metastases. Liora Lazar MD
Pediatric Thyroid Cancer Lung Metastases Liora Lazar MD Differentiated thyroid cancer (DTC) The 3rd most common solid tumor in childhood and adolescence Accounting for 1.5%-3% of all childhood cancers
More information- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer
Thyroid Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: 1. Lenvina is the first line therapy with powerful durable response and superior PFS in pts with RAI-refractory disease.
More informationThyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting?
Thyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting? Jacob Moalem, MD, FACS Associate Professor Endocrine Surgery and Endocrinology URMC Agenda 1. When is lobectomy alone
More informationDifferentiated Thyroid Carcinoma
Differentiated Thyroid Carcinoma The GOOD cancer? Jennifer Sipos, MD Associate Professor of Medicine Director, Benign Thyroid Program Division of Endocrinology, Diabetes and Metabolism The Ohio State University
More information(Not so) New Guidelines for Management of Thyroid Nodules and Differentiated Thyroid Cancer Minnesota/Midwest Chapter of AACE
(Not so) New Guidelines for Management of Thyroid Nodules and Differentiated Thyroid Cancer Minnesota/Midwest Chapter of AACE Bryan R. Haugen, MD University of Colorado, School of Medicine Outline Some
More informationTHYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine
THYROID CANCER IN CHILDREN Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine Thyroid nodules Rare Female predominance 4-fold as likely to be malignant Hx Radiation exposure?
More informationRadioiodine-refractory DTC
Oncology: Radioiodine-refractory DTC New Developments in Giuseppe COSTANTE, MD, Head, Endocrinology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Targeted Therapies Targeted Treatments
More informationAdjuvant therapy for thyroid cancer
Carcinoma of the thyroid Adjuvant therapy for thyroid cancer John Hay Department of Radiation Oncology Vancouver Cancer Centre Department of Surgery UBC 1% of all new malignancies 0.5% in men 1.5% in women
More informationPersistent & Recurrent Differentiated Thyroid Cancer
Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of
More informationThyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA
Thyroid Nodules ENDOCRINOLOGY DIVISION ENDOCRINOLOGY DIVISION Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA Anatomical Considerations The Thyroid Nodule Congenital anomalies Thyroglossal
More information5/3/2017. Ahn et al N Engl J Med 2014; 371
Alan Failor, M.D. Clinical Professor of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington April 20, 2017 No disclosures to report 1. Appropriately evaluate s in adult
More information42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%
Pinhole images of the neck are acquired in multiple projections, 24hrs after the oral administration of approximately 200 µci of I123. Usually, 24hr uptake value if also calculated (normal 24 hr uptake
More information3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women
Thyroid cancer- what s new Thyroid Cancer Changing epidemiology Molecular markers Lymph node dissection Technical advances rhtsh Genetic testing and prophylactic surgery Vandetanib What s new? Jessica
More information131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans
131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans Anca M. Avram, M.D. Associate Professor of Radiology Department of Nuclear Medicine University of Michigan Ann Arbor,
More informationThyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.
Thyroid Nodule Evaluating the patient with a thyroid nodule and some management options. Miguel V. Valdez PA C Disclosure Nothing to disclose. Learning Objectives Examination of thyroid gland Options for
More informationPre-operative Ultrasound of Lymph Nodes in Thyroid Cancer
Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel
More informationA variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study
ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD
More informationAACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration
AACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration Dr. Peter Singer, Endocrinology Dr. Peter Sadow, Pathology Moderator Dr. Greg Randolph, Otolaryngology Relevant Financial
More informationUltrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer
Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,
More informationSonographic Features of Thyroid Nodules & Guidelines for Management
Sonographic Features of Thyroid Nodules & Guidelines for Management Mark A. Lupo, MD, FACE, ECNU Thyroid & Endocrine Center of Florida Assistant Clinical Professor of Medicine Florida State University,
More informationImaging in Thyroid Cancer
Imaging in Thyroid Cancer Susan J. Mandel MD MPH University of Pennsylvania School of Medicine Philadelphia, PA I-123 Ultrasound Background Radioiodine ablation of thyroid remnants after surgery is a generally
More informationWhat s an NIFTP? Keeping Up To Date in Thyroid 2018
What s an NIFTP? Keeping Up To Date in Thyroid 2018 Kathleen Hands, MD, FACE, ECNU Director, Thyroid Center of South Texas Assistant Clinical Professor UTHSCSA DrHands@Thyroid-Center.com 210-844-6163 text
More informationEvaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada
Evaluation and Management of Thyroid Nodules Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada Disclosure Consulting Amgen Speaking Amgen Objectives Understand the significance of incidental
More information2015 ATA Thyroid Nodule and DTC Guidelines: Perspectives from the Chair What were you thinking????
2015 ATA Thyroid Nodule and DTC Guidelines: Perspectives from the Chair What were you thinking???? Bryan R. Haugen, MD University of Colorado, School of Medicine Outline Some statistics New guidelines
More informationManagement guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007
Management guideline for patients with differentiated thyroid Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Incidence (Srinagarind Hospital, 2005, both sex) Site (all) cases % 1. Liver 1178 27 2. Lung
More informationEvaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam
Overview of Thyroid Nodules and Their Management Matthew D. Ringel, M.D. Professor of Medicine Divisions of Endocrinology and Oncology, The Ohio State University Co-Director, Thyroid Cancer Unit Arthur
More informationKey Topics in Thyroid Cancer Worldwide epidemic What Should the Endocrinologist and Surgeon do?
Key Topics in Thyroid Cancer Worldwide epidemic What Should the Endocrinologist and Surgeon do? Martin Schlumberger Gustave Presenter Roussy Name and Université Paris Saclay, Villejuif, France 1 Disclosure
More information34 year-old Female with Thyroid Cancer
34 year-old Female with Thyroid Cancer KATIE O SULLIVAN, MD FELLOW, ADULT/PEDIATRIC ENDOCRINOLOGY UNIVERSITY OF CHICAGO ENDORAMA THURSDAY, SEPTEMBER 15 TH, 2016 Disclosures: I do not have any relevant
More informationObjectives. How to Investigate Thyroid Nodules like A Pro
How to Investigate Thyroid Nodules like A Pro Chris Sadler, MA, PA C, CDE, DFAAPA Medical Science Outcomes Liaison Intarcia Diabetes and Endocrine Associates La Jolla, CA Past President ASEPA Disclosures
More informationCitation Annals of Surgical Oncology, 2013, v. 20 n. 2, p
Title Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma
More informationCase Scenario 1: Thyroid
Case Scenario 1: Thyroid History and Physical Patient is an otherwise healthy 80 year old female with the complaint of a neck mass first noticed two weeks ago. The mass has increased in size and is palpable.
More informationObjectives. 1)To recall thyroid nodule ultrasound characteristics that increase the risk of malignancy
Evaluation and Management of Thyroid Nodules in Primary Care Chris Sadler, MA, PA C, CDE, DFAAPA Medical Science Outcomes Liaison Intarcia Diabetes and Endocrine Associates La Jolla, CA Past President
More informationProphylactic Central Compartment Neck Dissection(CCND) for Papillary Thyroid Cancer: Con
Prophylactic Central Compartment Neck Dissection(CCND) for Papillary Thyroid Cancer: Con Christopher R. McHenry, M.D. Vice Chairman Department of Surgery MetroHealth Medical Center Professor of Surgery
More informationTHYROID CANCER IN CHILDREN
THYROID CANCER IN CHILDREN Isabel ROCA, Montserrat NEGRE Joan CASTELL HU VALL HEBRON BARCELONA EPIDEMIOLOGY ADULTS males 1,2-2,6 cases /100.000 females 2,0-3,8 cases /100.000 0,02-0,3 / 100.000 children
More informationDisclosures Nodal Management in Differentiated Thyroid Carcinoma
Disclosures Nodal Management in Differentiated Thyroid Carcinoma Nothing to disclose Jonathan George, MD, MPH Assistant Professor UCSF Head and Neck Oncologic & Endocrine Surgery Objectives Overview Describe
More informationManagement of Thyroid Nodules. February 2 nd, 2018 Sarah Hopkins
Management of Thyroid Nodules February 2 nd, 2018 Sarah Hopkins No disclosures Goals: Review Initial Evaluation of Thyroid Nodules Review Indications for Biopsy Approach to Multinodular Goiter Review Management
More informationDilemmas in Cytopathology and Histopathology
Dilemmas in Cytopathology and Histopathology Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center, USA Objectives Discuss new WHO classification
More informationWhat you need to know about Thyroid Cancer
What you need to know about Thyroid Cancer This booklet has been designed to help you to learn more about your thyroid cancer. It covers the most important areas and answers some of the frequently asked
More informationThyroid Cancer & rhtsh: When and How?
Thyroid Cancer & rhtsh: When and How? 8 th Postgraduate Course in Endocrine Surgery Capsis Beach, Crete, September 21, 2006 Quan-Yang Duh, Professor of Surgery, UCSF Increasing Incidence of Thyroid Cancer
More informationThyroid Nodules. Family Medicine Refresher Course Geeta Lal MD, FACS April 2, No financial disclosures
Thyroid Nodules Family Medicine Refresher Course Geeta Lal MD, FACS April 2, 2014 No financial disclosures Objectives Review epidemiology Work up of Thyroid nodules Indications for FNAB Evolving role of
More informationThyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary
Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with
More informationCurrent Issues in Thyroid Cancer Surgery in 2017
Current Issues in Thyroid Cancer Surgery in 2017 Dr. David Goldstein MD Msc FRCSC FACS Associate Professor, Department Otolaryngology Head & Neck Surgery, U of T Department of Surgical Oncology, Princess
More informationClinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease
Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease Robert L. Ferris, MD, PhD Department of Otolaryngology/Head and Neck Surgery and Yuri E. Nikiforov, MD, PhD Division of
More informationExercise 15: CSv2 Data Item Coding Instructions ANSWERS
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report
More informationDifferentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment
ORIGINAL ARTICLE Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment Martínez MP, Lozano Bullrich MP, Rey M, Ridruejo MC, Bomarito MJ, Claus
More informationRESEARCH ARTICLE. Comparison of Presentation and Clinical Outcome between Children and Young Adults with Differentiated Thyroid Cancer
RESEARCH ARTICLE Comparison of Presentation and Clinical Outcome between Children and Young Adults with Jian-Tao Wang 1,2&, Rui Huang 1&, An-Ren Kuang 1 * Abstract Background: The aim of the present study
More information40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016
Outcomes from the diagnostic approach of thyroid lesions using US-FNA and LBC in clinical practice Emmanouel Mastorakis MD PhD Cytopathologist Director in Cytopathology Laboratory Regional General Hospital
More informationTania Gallant MD, FRCPC Internal Medicine Update April
Tania Gallant MD, FRCPC Internal Medicine Update April 28 2017 Disclosures Honoraria/Ad board: Sanofi-Aventis, Janssen, Merck Frosst, Eli-Lilly, Astra Zeneca, Boehringer-Ingelheim Objectives By the end
More informationThyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect
Thyroid Pathology: It starts and ends with the gross Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for
More informationReference No: Author(s) Approval date: October committee. September Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) guidelines for Thyroid cancer Dr Fionnuala Houghton Consultant Clinical Oncologist & Dr Lois Mulholland Consultant Clinical Oncologist
More informationReoperative central neck surgery
Reoperative central neck surgery R. Pandev, I. Tersiev, M. Belitova, A. Kouizi, D. Damyanov University Clinic of Surgery, Section Endocrine Surgery University Hospital Queen Johanna ISUL Medical University
More information10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary
Surgery for Well-differentiated Thyroid Carcinoma- The Primary Head and Neck Endocrine Surgery Department of Otolaryngology-Head and Neck Surgery, UCSF October 24-25, 2008 Robert A. Sofferman, MD Professor
More informationSuccess rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan
ORIGINAL ARTICLE Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan I. Hommel 1 *, G.F. Pieters 1, A.J.M. Rijnders 2, M.M. van Borren 3, H. de
More informationReview Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update
Bangladesh J Otorhinolaryngol 2010; 16(2): 126-130 Review Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update Md. Abdul Mobin Choudhury 1, Md. Abdul Alim Shaikh
More informationCalcitonin. 1
Calcitonin Medullary thyroid carcinoma (MTC) is characterized by a high concentration of serum calcitonin. Routine measurement of serum calcitonin concentration has been advocated for detection of MTC
More informationPRACTICE GUIDELINES: Thyroid Nodules and Cancer 2017 ESEO Alexandria
PRACTICE GUIDELINES: Thyroid Nodules and Cancer 2017 ESEO Alexandria James V. Hennessey MD Associate Professor of Medicine Harvard Medical School Case 1 28 year old woman sees OB for routine visit ROS:
More informationThyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version March 31, NCCN.org.
+ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2017 March 31, 2017 NCCN.org Continue Version 1.2017, 03/31/2017 National Comprehensive Cancer Network, Inc. 2017, All rights
More informationLong Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience
Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience Geoffrey B. Thompson, MD Professor of Surgery College of Medicine, Mayo Clinic Differentiated Thyroid Cancer Objectives Overview
More informationThyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
+ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2016 NCCN.org Continue Version 1.2016, 07/08/2016 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The
More informationTHYROID FUNCTION TEST and RADIONUCLIDE THERAPY
THYROID FUNCTION TEST and RADIONUCLIDE THERAPY Ajalaya Teyateeti, M.D. Division of Nuclear Medicine Department of Radiology I. Thyroid function test OUTLINE Application and interpretation of in vitro TFT
More informationThyroid US. Background: Thyroid/Neck US. Use of Office Ultrasound in the Thyroid Surgery Practice
2010 UCSF Head and Neck Endocrine Surgery Course Use of Office Ultrasound in the Thyroid Surgery Practice Lisa A. Orloff, MD FACS Dept of Otolaryngology-Head and Neck Surgery University of California,
More informationATA Guidelines for Medullary Thyroid Cancer: approach to initial management of sporadic and inherited disease
ATA Guidelines for Medullary Thyroid Cancer: approach to initial management of sporadic and inherited disease Richard T. Kloos, M.D. The Ohio State University Divisions of Endocrinology and Nuclear Medicine
More informationLocally advanced papillary thyroid cancer
Locally advanced papillary thyroid cancer Educational Session 12 th October 2015 Presenters: Smith JA, Carr-Boyd E Supervisors: Palme CE, Elliott M, Navin N, Gupta R Content Case report Imaging Primary
More informationIntegrating Guidelines, Experience, and Clinical Judgment in the Management of Thyroid Cancer AACE Annual Meeting May 5, 2016
Integrating Guidelines, Experience, and Clinical Judgment in the Management of Thyroid Cancer AACE Annual Meeting May 5, 2016 Bryan Haugen, M.D. Julie Ann Sosa, M.D. Mike Tuttle, M.D. Peter A. Singer,
More informationRESEARCH ARTICLE. Importance of Postoperative Stimulated Thyroglobulin Level at the Time of 131 I Ablation Therapy for Differentiated Thyroid Cancer
RESEARCH ARTICLE Importance of Postoperative Stimulated Thyroglobulin Level at the Time of 131 I Ablation Therapy for Differentiated Thyroid Cancer Zekiye Hasbek 1 *, Bulent Turgut 1, Fatih Kilicli 2,
More informationCarcinoma tiroideo differenziato: gestione della persistenza biochimica di malattia
Carcinoma tiroideo differenziato: gestione della persistenza biochimica di malattia Massimo Torlontano U.O. Endocrinologia IRCCS Casa Sollievo della Sofferenza Thyroid cancer Incidence 1975-2009 (USA)
More informationThe use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer
The use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer Wendy Sacks, M.D. Cedars Sinai Medical Center California Chapter Annual Meeting, AACE Nov 5, 2016 Increasing Incidence of Thyroid Cancer
More information5/18/2013. Most thyroid nodules are benign. Thyroid nodules: new techniques in evaluation
Most thyroid nodules are benign Thyroid nodules: new techniques in evaluation Incidence Etiology Risk factors Diagnosis Gene classification system Treatment Postgraduate Course in General Surgery Jessica
More informationThyroid Cancer: Imaging Techniques (Nuclear Medicine)
Thyroid Cancer: Imaging Techniques (Nuclear Medicine) Andrei Iagaru, MD MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology Introduction Ø There are
More informationCase Scenario #1 Larynx
Case Scenario #1 Larynx 56 year old white female who presented with a 2 month history of hoarseness treated with antibiotics, but with no improvement. In the last 3 weeks, she has had a 15 lb weight loss,
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More informationDistant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination
Endocrine Journal 2008, 55 (5), 889 894 Distant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination YASUHIRO ITO, TOMONORI
More informationChanging trends in the management of well-differentiated thyroid carcinoma in Korea
2016, 63 (6), 515-521 Original Changing trends in the management of well-differentiated thyroid carcinoma in Korea Yong Sang Lee, Hang-Seok Chang and Cheong Soo Park Thyroid Cancer Center, Department of
More informationThyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2014 NCCN.org Continue Version 2.2014, 08/12/2014 National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN
More informationUSGFNA of thyroid nodules
US Guided FNA (USGFNA) of neck masses INTERVENTIONAL HEAD & NECK ULTRASOUND Brendan C. Stack, Jr., MD., FACS, FACE Professor Otolaryngology-Head and Neck Surgery Indications Technique Interpretation Results
More informationAmerican College of Radiology ACR Appropriateness Criteria
American College of Radiology ACR Criteria Thyroid Carcinoma Variant 1: T1a N0 M0 papillary thyroid cancer: 40-year-old woman. 30 mci with thyrotropin 100 mci with thyrotropin 30 mci with thyroid hormone
More informationThyroglobulin Interference in the Determination of Thyroglobulin Antibody in Wash-Out Fluid from Fine Needle Aspiration Biopsy of Lymph Node
ORIGINAL ARTICLE Thyroglobulin Interference in the Determination of Thyroglobulin Antibody in Wash-Out Fluid from Fine Needle Aspiration Biopsy of Lymph Node Ibáñez N 1, Cavallo A.C 2, Smithuis F 1, Negueruela
More informationSurgical Management of Thyroid Disease. Tom Shi Connally, MD, FACS
Surgical Management of Thyroid Disease Tom Shi Connally, MD, FACS Disclosures Speaker Bureau: Veracyte Castle Diagnostics Objectives Understand the role of ultrasound and FNA in managing thyroid cancer
More information